These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 21158921)

  • 41. Long-term results after conversion from calcineurin inhibitors to sirolimus in renal transplant patients.
    Martinez-Mier G; Avila-Pardo SF; Mendez-Lopez MT; Budar-Fernandez LF
    Clin Transplant; 2010; 24(4):467-73. PubMed ID: 19744089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Calcineurin inhibitor-free immunosuppression using everolimus (Certican) in maintenance heart transplant recipients: 6 months' follow-up.
    Rothenburger M; Teerling E; Bruch C; Lehmkuhl H; Suwelack B; Bara C; Wichter T; Hinder F; Schmid C; Stypmann J
    J Heart Lung Transplant; 2007 Mar; 26(3):250-7. PubMed ID: 17346627
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Everolimus with reduced-dose cyclosporine in de novo renal transplant recipients: Philippine experience.
    Li JT; Danguilan RA; Cabanayan-Casasola CB; Talusan-Tomacruz Y; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2211-3. PubMed ID: 18790195
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of long-term calcineurin inhibitor therapy on renal function in children after liver transplantation.
    Arora-Gupta N; Davies P; McKiernan P; Kelly DA
    Pediatr Transplant; 2004 Apr; 8(2):145-50. PubMed ID: 15049794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Conversion to everolimus in liver transplant patients with renal dysfunction.
    Pérez T; Segovia R; Castro L; Roblero JP; Estela R
    Transplant Proc; 2011; 43(6):2307-10. PubMed ID: 21839260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients.
    Sánchez Fructuoso A; Ruiz San Millán JC; Calvo N; Rodrigo E; Moreno MA; Cotorruelo J; Conesa J; Gómez-Alamillo C; Arias M; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2148-50. PubMed ID: 17889120
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Conversion to everolimus monotherapy in maintenance liver transplantation: feasibility, safety, and impact on renal function.
    De Simone P; Carrai P; Precisi A; Petruccelli S; Baldoni L; Balzano E; Ducci J; Caneschi F; Coletti L; Campani D; Filipponi F
    Transpl Int; 2009 Mar; 22(3):279-86. PubMed ID: 19054383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency.
    Peddi VR; Jensik S; Pescovitz M; Pirsch J; Adler SH; Thistlethwaite JR; Vincenti F; Cohen DJ
    Clin Transplant; 2005 Feb; 19(1):130-6. PubMed ID: 15659146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus in lung transplantation in Chile.
    Parada MT; Alba A; Sepúlveda C
    Transplant Proc; 2010; 42(1):328-30. PubMed ID: 20172343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience with Certican (everolimus) in maintenance heart transplant patients at the Medical University of Vienna.
    Zuckermann A
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S206-9; discussion S210-1. PubMed ID: 15774324
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial.
    Dantal J; Berthoux F; Moal MC; Rostaing L; Legendre C; Genin R; Toupance O; Moulin B; Merville P; Rerolle JP; Bayle F; Westeel PF; Glotz D; Kossari N; Lefrançois N; Charpentier B; Quéré S; Di Giambattista F; Cassuto E;
    Transpl Int; 2010 Nov; 23(11):1084-93. PubMed ID: 20500493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease.
    Thimonier E; Guillaud O; Walter T; Decullier E; Vallin M; Boillot O; Dumortier J
    Clin Transplant; 2014 Dec; 28(12):1339-48. PubMed ID: 25081431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: Results from a multicenter, prospective study.
    Ganschow R; Ericzon BG; Dhawan A; Sharif K; Martzloff ED; Rauer B; Ng J; Lopez P
    Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28714558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Refractory autoimmune hemolytic anemia after intestinal transplant responding to conversion from a calcineurin to mTOR inhibitor.
    Acquazzino MA; Fischer RT; Langnas A; Coulter DW
    Pediatr Transplant; 2013 Aug; 17(5):466-71. PubMed ID: 23730873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rejection after conversion to a proliferation signal inhibitor in chronic heart transplantation.
    González-Vílchez F; Vázquez de Prada JA; Paniagua MJ; Almenar L; Mirabet S; Gómez-Bueno M; Díaz-Molina B; Arizón JM; Delgado J; Pérez-Villa F; Crespo-Leiro MG; Martínez-Dolz L; Roig E; Segovia J; Lambert JL; Lopez-Granados A; Escribano P; Farrero M
    Clin Transplant; 2013; 27(6):E649-58. PubMed ID: 24025040
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity.
    Bilbao I; Dopazo C; Castells L; Lazaro J; Caralt M; Sapisochin G; Charco R
    Transplant Proc; 2014 Nov; 46(9):3104-7. PubMed ID: 25420835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. mTOR inhibitors in pediatric liver transplant recipients.
    Dumortier J; Couchonnal E; Lacaille F; Rivet C; Debray D; Boillot O; Lachaux A; Ackermann O; Gonzales E; Wildhaber BE; Jacquemin E; McLin V
    Clin Res Hepatol Gastroenterol; 2019 Aug; 43(4):403-409. PubMed ID: 30528864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years.
    Engelen MA; Welp HA; Gunia S; Amler S; Klarner MP; Dell'aquila AM; Stypmann J
    Ann Thorac Surg; 2014 Mar; 97(3):888-93. PubMed ID: 24206966
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.